Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi

18 Sep 2023
www.biospace.com
Acquisition
Deal sees Pharmanovia acquire 11 brands within CNS, including Frisium® (clobazam) and Gardenal® (phenobarbital) Portfolio available in 60+ markets and deepens our CNS footprint in Brazil, South Africa, France and Italy Strong CNS franchise fits with Pharmanovia’s existing neurology portfolio and commercial capabilities BASILDON, England--(BUSINESS WIRE)-- PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY This press release features multimedia. View the full release here: James Burt, CEO, Pharmanovia (Photo: Business Wire) Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. The brands span four therapy areas of ongoing unmet need associated with CNSCNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.1 The acquired brands include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® may also be used as adjunctive therapy in epilepsy.1 Phenobarbital (brand: Gardenal®*) is used as an anti-convulsant to treat all forms of epilepsy except absence seizures.2 Cyamemazine (brand: Tercian®*†) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant.3 Prochlorperazine (brand: Stemetil®*) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety.4,5 Dr James Burt, Pharmanovia CEO, commented: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium® and Gardenal®, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.” “Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.” -Ends- Notes to editors *Not all indications are approved in every market. For local indications it is advised to check the local approved label. †Tercian® is only available in France. About Pharmanovia Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships. Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology. For more information about Pharmanovia, please visit About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: to chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. References 1 - Frisium Summary of Product Characteristics, – last accessed 11.9.2023 2 - Phenobarbital Sodium Injection Summary of Product Characteristics, - last accessed 11.9.2023 3 - Terican Summary of Product Characteristics, – last accessed 11.9.2023 4 - Stemetil Injection Summary of Product Characteristics, - last accessed 11.9.2023 5 - Stemetil Tablets Summary of Product Characteristics, - last accessed 11.9.2023 COR2023PR00207 – Date of Preparation – 14.9.2023 View source version on businesswire.com: Contacts Alison Dyson, Director of Communications, Pharmanovia +44 7442 256310/alison.dyson@pharmanovia.com or pharmanovia@67health.co.uk Source: Pharmanovia Smart Multimedia Gallery Photo James Burt, CEO, Pharmanovia (Photo: Business Wire) Logo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.